Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in the Bank of America Merrill Lynch Global Healthcare Conference.
Details for the event are as follows:
| Bank of America Merrill Lynch Global Healthcare Conference | ||
| Date: | Tuesday, May 10, 2022 | |
| Time: | 9:20am PDT | |
| Webcast Link: | https://bofa.veracast.com/webcasts/bofa/hc2022/id6InQpA.cfm | |
A webcast of the presentation will be available on the Investors section of the Company’s website for 90 days following the presentation.
About Krystal Biotech
Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to develop life-changing treatment options for patients with serious diseases, including rare diseases in skin, lung, and other areas. For more information, please visit http://www.krystalbio.com and follow @KrystalBiotech on LinkedIn and Twitter.
CONTACT:
Investors and Media:
Meg Dodge
Krystal Biotech
This email address is being protected from spambots. You need JavaScript enabled to view it.
Source: Krystal Biotech, Inc.
| Last Trade: | US$136.94 |
| Daily Change: | 4.32 3.26 |
| Daily Volume: | 259,653 |
| Market Cap: | US$3.940B |
April 28, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
